Shares of Wockhardt slump 6 percent intraday Monday on drug recall concerns. Over 200 bottles of Captopril tablets, used in treatment of blood pressure, and Clarithromycin antibiotic tablets manufactured by Wockhardt are being recalled in the US due to deviations in current good manufacturing practice norms laid down by US Food and Drug Administration (FDA).
According to information on the US health regulator's website, 166 bottles of Captopril tablets of 50 mg strength are being recalled in the US.
In case of Clarithromycin, the recall is for 50 bottles containing tablets of 500 mg strength.
The recall is made by Blenheim Pharmacal Inc, which packages and repackages Captopril and Clarithromycin, respectively.
The FDA said the reason for the recall is "cGMP" (current good manufacturing practice) deviations and current good manufacturing practice.
In both the cases, the products are being recalled "in response to a recall notice from the manufacturer, Wockhardt, following a FDA inspection which noted inadequate investigation of market complaints, resulting in unsuccessful identification of root causes, and the investigation not being expanded to prevent repeat failure", it added.
Both the recalls are classified as Class II, "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote".
At 14:55 hrs Wockhardt was quoting at Rs 1,308.50, down Rs 64.90, or 4.73 percent on the BSE.
With inputs from PTI
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
